The addition of tremelimumab to frontline durvalumab and platinum-based chemotherapy did not demonstrate a statistically significant improvement in overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC), missing the co-primary endpoint of the phase 3 CASPIAN study.
Presented by Prof. Luis Paz-Ares (Hospital 12 de Octubre, Madrid, Spain), this was the first report of the third study arm of CASPIAN, in which the investigational CTLA-4 inhibitor tremelimumab was added to PD-L1 checkpoint inhibitor durvalumab on top of standard of care chemotherapy .
CASPIAN randomised 805 patients to 3 treatment arms: durvalumab + tremelimumab + etoposide cisplatin/carboplatin (EP; n=268), EP alone (n=269), or durvalumab + EP (n=268). The primary endpoint of the study was OS; secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and s...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Carfilzomib: no PFS benefit for multiple myeloma Next Article
Adjuvant osimertinib in NSCLC: practice changing ADAURA trial »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.